Holen Sie sich die Stockscreener-App
5.695
4.92%
-0.305
Schlusskurs vom Vortag:
$6.00
Offen:
$5.96
24-Stunden-Volumen:
564.33K
Relative Volume:
0.53
Marktkapitalisierung:
$292.00M
Einnahmen:
$676.80M
Nettoeinkommen (Verlust:
$-8.60M
KGV:
-20.13
EPS:
-0.2829
Netto-Cashflow:
$135.40M
1W Leistung:
-11.69%
1M Leistung:
+17.87%
6M Leistung:
-31.68%
1J Leistung:
-30.93%
1-Tages-Spanne:
$5.6509
$6.04
1-Wochen-Bereich:
$5.6509
$6.60
52-Wochen-Spanne:
$4.36
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
5.695 | 307.64M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
18.25 | 58.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.68 | 42.84B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.235 | 40.68B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.17 | 30.40B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
504.42 | 21.36B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - GlobeNewswire Inc.
Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha
Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us
Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioS - The National Law Review
Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com Australia
Emergent BioSolutions Repurchases $75 Million of Debt at Discount - citybiz
Emergent BioSolutions faces securities fraud pr... - Pluang
Gaithersburg's Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS - BioBuzz
Emergent BioSolutions repurchases $75 million in senior notes - Investing.com
Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes, Reducing Debt to $364.7 Million - Quiver Quantitative
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Reach Out - ACCESS Newswire
Emergent BioSolutions | 8-K: Current report - Moomoo
Emergent BioSolutions receives $24 million BARDA contract - grafa.com
2026-09-01 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Shareholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
Emergent BioSolutions Inc. Receives Contract Modification Valued At Approximately USD 24 Million From The Biomedical Advanced Research And Development Authority To Supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) - marketscreener.com
Emergent BioSolutions receives $24M anthrax vaccine contract By Investing.com - Investing.com Australia
EBS Looks 11.9% Overvalued on GF Value™ Amid Challenging Growth Outlook - GuruFocus
Emergent BioSolutions receives $24M anthrax vaccine contract - Investing.com
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - The Manila Times
Emergent BioSolutions Awarded $24M CYFENDUS Contract | EBS Stock News - Stock Titan
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray - Bioscience Association Manitoba
EBS Looks 8.4% Overvalued on GF Value™ Amid Challenging Growth O - GuruFocus
Emergent BioSolutions wins Canada contract for overdose spray By Investing.com - Investing.com Nigeria
Emergent BioSolutions wins Canada contract for overdose spray - Investing.com Canada
Emergent BioSolutions Awarded Canadian Government Standing Offer for NARCAN Nasal Spray - Quiver Quantitative
Canadian public agencies can buy NARCAN for three years; the spray lasts four - Stock Titan
Emergent BioSolutions Expands Ready to Rescue Campaign on U.S. Campuses and in Canada for International Overdose Awareness Day - Quiver Quantitative
2026-08-30 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Investors to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
Emergent BioSolutions Inc. (EBS) Options Chain - finance.yahoo.com
Emergent Biosolutions Inc (EBS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Stockholders to Reach Out - ACCESS Newswire
EBS Reinstated by JP Morgan -- Current Rating Underweight - GuruFocus
2026-08-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Stockholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS) - MarketBeat
EBS Looks 11.9% Undervalued on GF Value™ Despite Underweight Rat - GuruFocus
J.P. Morgan Initiates Emergent BioSolutions(EBS.US) With Sell Rating - Moomoo
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Emergent (EBS) Price: Gains 4.94% to Reach $4.89 at the Close; Immediate View: the Near-Term Reference Band Stretches From $4.65 to $5.13 on the DayPrice Target - vinanet.vn
Emergent BioSolutions Balances Q2 Beat With Tough Outlook - The Globe and Mail
S&P downgrades Emergent BioSolutions outlook on competition By Investing.com - Investing.com Nigeria
S&P downgrades Emergent BioSolutions outlook on competition - Investing.com
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Emergent BioSolutions (EBS) Holds Above Support as Shares Slip 0.33%Volume Oscillator - vinanet.vn
Emergent BioSolutions Inc (EBS) (Q2 2026) Earnings Call Highligh - GuruFocus
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law - Business Wire
Emergent BioSolutions Restructures - Contract Pharma
Emergent BioSolutions (EBS) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Emergent Biosolutions Inc. (NYSE:EBS) Given Average Rating of "Hold" by Analysts - MarketBeat
Q2 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
1.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):